Recent U.S. Customs and Border Protection rulings from CROSS, searchable by HTS code, keyword, or ruling number.
In your letter dated March 11, 2026, you requested a tariff classification ruling. ZEPIZURE (Midazolam Injection) is in a class of drugs known as benzodiazepine. In your letter, you stated the subject product consists of an injectable midazolam formulation in 10 mg/0.625 mL contained in a prefilled, single-dose, single-use, needle-free ZENEO® auto-injector, intended exclusively for intramuscular administration and packaged in a box of 10 units. The pictures you submitted, state the product is indicated for epileptic emergencies.
Source: rulings.cbp.gov (CROSS). This index holds New York rulings from the recent period and the Headquarters rulings they cite. It is not the full CROSS database of 222,467 rulings, and it does not hold every Headquarters ruling. New rulings usually appear here within a few days of CBP publishing them; a ruling published long after its number was assigned can take several weeks. Revoked, modified and proposed marks come from the weekly Customs Bulletin, where CBP publishes most such actions under 19 U.S.C. 1625(c), read here from the Nov 2024 issues onward, and from the subjects of indexed Headquarters rulings. A revocation is marked from the date it takes effect. The absence of a mark is not confirmation that a ruling is still in effect. A ruling letter is binding on CBP only for the particular transaction or issue it describes (19 CFR 177.9). Confirm the text and status on CROSS before relying on a ruling. Not legal advice.